$CureVac (CVAC.US)$CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany Benzinga· 1 min ago New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
CureVac股票讨论
在2024年ESMO大会上
德国图宾根/美国波士顿 – 2024年9月9日 – 纳斯达克CVAC股票代号(“CureVac”)今天宣布,CureVac正在进行的CVGBm癌症疫苗1期临床研究的首批临床数据显示,该疫苗针对患有重大疾病的患者...
CureVac将癌症疫苗候选CVGBm推进到1期研究的第二部分b
治愈疫苗在患有切除的胶质母细胞瘤的患者中进行
·第一个患者接受了基于mRNA的多表位癌症疫苗候选CVGBm的剂量确认1期研究的部分b
·预计部分b将包括最多20名患者,以生成有关安全性、耐受性和免疫反应的扩展数据
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
暂无评论